Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT) - Centre Eugène Marquis Accéder directement au contenu
Article Dans Une Revue European Journal of Cancer Année : 2024

Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)

1 UGA - Université Grenoble Alpes
2 IAB - Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble)
3 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
4 Centre Léon Bérard [Lyon]
5 Hôpital privé Jean Mermoz [Lyon]
6 CHU de Bordeaux - Centre Hospitalier Universitaire de Bordeaux
7 Université de Lille
8 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
9 OncoThAI - Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189
10 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
11 CHU Caen
12 SU - Sorbonne Université
13 CHU Saint-Antoine [AP-HP]
14 AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris]
15 Institut Curie [Paris]
16 PSL - Université Paris Sciences et Lettres
17 IGR - Institut Gustave Roussy
18 IPC - Institut Paoli-Calmettes
19 CHUV - Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne]
20 CRLCC - CRLCC Eugène Marquis
21 UM - Université de Montpellier
22 CHRU Montpellier - Hôpital Saint Eloi
23 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
24 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
25 CHU Dijon
26 LNC - Lipides - Nutrition - Cancer [Dijon - U1231]
27 OSS - Oncogenesis, Stress, Signaling
28 NGERE - Nutrition-Génétique et Exposition aux Risques Environnementaux
29 LNC - Lipides - Nutrition - Cancer (U866)
30 IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole
31 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
32 UVSQ - Université de Versailles Saint-Quentin-en-Yvelines
33 Université Paris-Saclay
34 UPCité - Université Paris Cité
35 CRI (UMR_S_1149 / ERL_8252 / U1149) - Centre de recherche sur l'Inflammation
36 Hôpital Beaujon [AP-HP]
37 Mécanismes cellulaires et moléculaires de l'adaptation au stress et cancérogenèse
38 CHB - Centre Hépato-Biliaire [Hôpital Paul Brousse]
39 IMM - Institut Mutualiste de Montsouris
40 CANTHER - Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277
41 AP-HP Hôpital universitaire Robert-Debré [Paris]
Loic Verlingue
Matthieu Sarabi
Maxime Ronot
Christophe Louvet

Résumé

Introduction: This document is a summary of the French intergroup guidelines of the management of biliary tract cancers (BTC) (intrahepatic, perihilar and distal cholangiocarcinomas, and gallbladder carcinomas) published in September 2023, available on the website of the French Society of Gastroenterology (SNFGE) (www.tncd.org). Methods: This collaborative work was conducted under the auspices of French medical and surgical societies involved in the management of BTC. Recommendations were graded in three categories (A, B and C) according to the level of scientific evidence until August 2023. Results: BTC diagnosis and staging is mainly based on enhanced computed tomography, magnetic resonance imaging and (endoscopic) ultrasound-guided biopsy. Treatment strategy depends on BTC subtype and disease stage. Surgery followed by adjuvant capecitabine is recommended for localised disease. No neoadjuvant treatment is validated to date. Cisplatin-gemcitabine chemotherapy combined to the anti-PD-L1 inhibitor durvalumab is the first-line standard of care for advanced disease. Early systematic tumour molecular profiling is recommended to screen for actionable alterations (IDH1 mutations, FGFR2 rearrangements, HER2 amplification, BRAFV600E mutation, MSI/dMMR status, etc.) and guide subsequent lines of treatment. In the absence of actionable alterations, FOLFOX chemotherapy is the only second-line standard-of-care. No third-line chemotherapy standard is validated to date. Conclusion: These guidelines are intended to provide a personalised therapeutic strategy for daily clinical practice. Each individual BTC case should be discussed by a multidisciplinary team.
Fichier sous embargo
Fichier sous embargo
Fichier sous embargo
0 1 27
Année Mois Jours
Avant la publication
vendredi 13 septembre 2024
Fichier sous embargo
0 1 27
Année Mois Jours
Avant la publication
vendredi 13 septembre 2024
Fichier sous embargo
vendredi 13 septembre 2024
Connectez-vous pour demander l'accès au fichier

Dates et versions

hal-04626861 , version 1 (11-07-2024)

Licence

Identifiants

Citer

Gael S. Roth, Loic Verlingue, Matthieu Sarabi, Jean Frédéric Blanc, Emmanuel Boleslawski, et al.. Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT). European Journal of Cancer, 2024, 202, pp.114000. ⟨10.1016/j.ejca.2024.114000⟩. ⟨hal-04626861⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More